Reaction

Breast Swelling reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,672 reports · 59 co-occurring drugs

As of the last recalculation, Breast Swelling appears in 2,672 FAERS reports alongside 59 co-occurring drug terms. The strongest observed disproportionality signal is BICALUTAMIDE (PRR 13.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Bicalutamide	27	13.9	14.0
Levonorgestrel	284	12.2	12.2
Goserelin	20	11.7	11.7
Raloxifene Hydrochloride	20	10.7	10.8
Anastrozole	45	9.7	9.7
Drospirenone And Ethinyl Estradiol	51	9.1	9.2
Estradiol	97	9.0	9.0
Progesterone	23	7.9	7.9
Amitriptyline Hydrochloride	17	7.6	7.6
Etonogestrel And Ethinyl Estradiol	20	7.1	7.1
Paliperidone	21	7.1	7.1
Ribociclib	27	6.7	6.7
Finasteride	48	6.3	6.3
Desoximetasone	15	6.2	6.2
Lisinopril And Hydrochlorothiazide Tablets	6	6.0	6.0
Fulvestrant	24	5.7	5.7
Anastrozole Tablets	15	5.5	5.5
Estradiol Gel 0.1%	30	5.2	5.2
Estradiol Transdermal	30	5.2	5.2
Fexofenadine	11	5.2	5.2
Thyroid, Porcine	7	5.1	5.1
Eplerenone	8	4.9	4.9
Conjugated Estrogens	35	4.7	4.7
Estrogens, Conjugated	35	4.6	4.6
Lisinopril And Hydrochlorothiazide	6	4.6	4.6
Isosorbide Mononitrate	12	4.5	4.5
Leuprolide Acetate	42	4.3	4.3
Anakinra	9	4.2	4.2
Conjugated Estrogens And Medroxyprogesterone Acetate	12	4.0	4.0
Medroxyprogesterone Acetate	25	3.9	3.9
Dutasteride	4	3.8	3.8
Lurasidone Hydrochloride	10	3.7	3.7
Risperidone	62	3.7	3.7
Alpelisib	4	3.6	3.6
Etonogestrel	21	3.4	3.4
Vortioxetine	7	3.2	3.2
Paliperidone Palmitate	13	3.2	3.2
Ivacaftor	3	2.9	2.9
Loratadine And Pseudoephedrine Sulfate	3	2.9	2.9
Enzalutamide	22	2.9	2.9
Ravulizumab	5	2.9	2.9
Asenapine Maleate	3	2.7	2.7
Voclosporin	3	2.7	2.7
Bimekizumab	7	2.6	2.6
Teriparatide	36	2.5	2.5
Alirocumab	8	2.5	2.5
Palbociclib	26	2.1	2.1
Apalutamide	3	2.0	2.0
Abemaciclib	5	2.0	2.0
Isotretinoin	12	1.9	1.9
Elexacaftor, Tezacaftor, And Ivacaftor	3	1.9	1.9
Abaloparatide	7	1.9	1.9
Orlistat	6	1.8	1.8
Varenicline Tartrate	18	1.8	1.8
Somatropin	16	1.7	1.7
Ixekizumab	8	1.7	1.7
Relugolix	5	1.7	1.7
Guselkumab	7	1.5	1.5
Copper	5	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.